MedTrace Logo

Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy

NCT03054883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2017-02-16

No results posted yet for this study

Summary

This is an observational study aimed to analyze the effectiveness of treatment of patients with newly dg. mantle cell lymphoma not eligible for high-dose therapy and autologous stem cell transplantation. Scheme of treatment: alternating cycles of R-CHOP (rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, prednison) and R-AraC (rituximab, cytarabin): R-CHOP / R-AraC / R-CHOP / R-AraC / R-CHOP / R-AraC. The study was proposed based on the previously published data in the younger patients, which demonstrated improved outcome after implementation of Ara-C into induction.

Conditions

Sponsors & Collaborators

  • Ministry of Health, Czech Republic

    collaborator OTHER_GOV

  • Czech Lymphoma Study Group

    lead OTHER

Principal Investigators

  • Marek Trneny, prof.,PhD. · Charles University General Hospital in Prague

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-01
Primary Completion
2015-12-31
Completion
2016-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03054883 on ClinicalTrials.gov